The Experts below are selected from a list of 11031 Experts worldwide ranked by ideXlab platform
Patrick Jahn - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European Oncology Nurse survey
Supportive Care in Cancer, 2019Co-Authors: Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick JahnAbstract:IntroductionPreventing CINV is possible when guideline-recommended antiemetics are used. Because Oncology Nurses play a critical role in risk assessment and management of CINV, a survey of European Nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence.MethodsFrom March 2016 to Feb 2017, 212 Oncology Nurses in 16 European countries completed a 20-question online survey.ResultsRespondents had 15-year (median) Oncology nursing experience, and most (75%) were able to suggest or prescribe antiemetics. Most (80%) worked in the public not-for-profit hospital setting. Guideline awareness was generally low with Nurses most familiar with ASCO (46%) and MASCC/ESMO (40%) guidelines; individual institution guidelines were most commonly used (47%). Key discrepancies between reported antiemetic use and guideline recommendations in the highly emetogenic chemotherapy (HEC) setting were underutilization of the recommended NK_1RA + 5-HT_3RA + steroid combination on day 1 (55%) and high use of 5-HT_3RAs (50%) on days 2–5 when a steroid (63% use) should be used. Metoclopramide use was high in both HEC and moderately emetogenic settings, with ~ 30% and ~ 50% reporting use on day 1 and days 2–5, respectively. The most common reported barrier to use of guideline-recommended agents was physician preference (40%). The most common challenges in managing CINV were “controlling nausea/vomiting in the delayed phase” (64%) and “reducing the impact of CINV on patients’ quality-of-life” (61%).ConclusionsThis survey highlights opportunities to improve utilization of guideline-recommended antiemetics, thereby optimizing prevention of CINV and QoL for patients receiving emetogenic chemotherapy.
-
evaluation of antiemetic practices for prevention of chemotherapy induced nausea and vomiting cinv results of a european Oncology Nurse survey
Supportive Care in Cancer, 2019Co-Authors: Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick JahnAbstract:Preventing CINV is possible when guideline-recommended antiemetics are used. Because Oncology Nurses play a critical role in risk assessment and management of CINV, a survey of European Nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence. From March 2016 to Feb 2017, 212 Oncology Nurses in 16 European countries completed a 20-question online survey. Respondents had 15-year (median) Oncology nursing experience, and most (75%) were able to suggest or prescribe antiemetics. Most (80%) worked in the public not-for-profit hospital setting. Guideline awareness was generally low with Nurses most familiar with ASCO (46%) and MASCC/ESMO (40%) guidelines; individual institution guidelines were most commonly used (47%). Key discrepancies between reported antiemetic use and guideline recommendations in the highly emetogenic chemotherapy (HEC) setting were underutilization of the recommended NK1RA + 5-HT3RA + steroid combination on day 1 (55%) and high use of 5-HT3RAs (50%) on days 2–5 when a steroid (63% use) should be used. Metoclopramide use was high in both HEC and moderately emetogenic settings, with ~ 30% and ~ 50% reporting use on day 1 and days 2–5, respectively. The most common reported barrier to use of guideline-recommended agents was physician preference (40%). The most common challenges in managing CINV were “controlling nausea/vomiting in the delayed phase” (64%) and “reducing the impact of CINV on patients’ quality-of-life” (61%). This survey highlights opportunities to improve utilization of guideline-recommended antiemetics, thereby optimizing prevention of CINV and QoL for patients receiving emetogenic chemotherapy.
Tracy K. Gosselin-acomb - One of the best experts on this subject based on the ideXlab platform.
-
Role of the radiation Oncology Nurse.
Seminars in oncology nursing, 2006Co-Authors: Tracy K. Gosselin-acombAbstract:Objectives To discuss the role of the radiation Oncology Nurse as changes in technology and treatment impact care delivery. Data Sources Published articles and texts, professional organizations, and the authors’ experience. Conclusion Patients receiving cancer treatment today face a myriad of treatment options that can be delivered over days, weeks, and months. As treatments become more complex and standard chemotherapy regimens are combined with new agents and targeted agents, radiation Oncology Nurses need to have the knowledge and skills to accurately assess and intervene. The radiation Oncology Nurse is the cornerstone of patient advocacy, care, and education. Implications for Nursing Practice Changes in treatment and technology continue to drive cancer care. Radiation Oncology Nurses need to collaborate with colleagues and incorporate evidence into practice.
Pascale Dielenseger - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European Oncology Nurse survey
Supportive Care in Cancer, 2019Co-Authors: Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick JahnAbstract:IntroductionPreventing CINV is possible when guideline-recommended antiemetics are used. Because Oncology Nurses play a critical role in risk assessment and management of CINV, a survey of European Nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence.MethodsFrom March 2016 to Feb 2017, 212 Oncology Nurses in 16 European countries completed a 20-question online survey.ResultsRespondents had 15-year (median) Oncology nursing experience, and most (75%) were able to suggest or prescribe antiemetics. Most (80%) worked in the public not-for-profit hospital setting. Guideline awareness was generally low with Nurses most familiar with ASCO (46%) and MASCC/ESMO (40%) guidelines; individual institution guidelines were most commonly used (47%). Key discrepancies between reported antiemetic use and guideline recommendations in the highly emetogenic chemotherapy (HEC) setting were underutilization of the recommended NK_1RA + 5-HT_3RA + steroid combination on day 1 (55%) and high use of 5-HT_3RAs (50%) on days 2–5 when a steroid (63% use) should be used. Metoclopramide use was high in both HEC and moderately emetogenic settings, with ~ 30% and ~ 50% reporting use on day 1 and days 2–5, respectively. The most common reported barrier to use of guideline-recommended agents was physician preference (40%). The most common challenges in managing CINV were “controlling nausea/vomiting in the delayed phase” (64%) and “reducing the impact of CINV on patients’ quality-of-life” (61%).ConclusionsThis survey highlights opportunities to improve utilization of guideline-recommended antiemetics, thereby optimizing prevention of CINV and QoL for patients receiving emetogenic chemotherapy.
-
evaluation of antiemetic practices for prevention of chemotherapy induced nausea and vomiting cinv results of a european Oncology Nurse survey
Supportive Care in Cancer, 2019Co-Authors: Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick JahnAbstract:Preventing CINV is possible when guideline-recommended antiemetics are used. Because Oncology Nurses play a critical role in risk assessment and management of CINV, a survey of European Nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence. From March 2016 to Feb 2017, 212 Oncology Nurses in 16 European countries completed a 20-question online survey. Respondents had 15-year (median) Oncology nursing experience, and most (75%) were able to suggest or prescribe antiemetics. Most (80%) worked in the public not-for-profit hospital setting. Guideline awareness was generally low with Nurses most familiar with ASCO (46%) and MASCC/ESMO (40%) guidelines; individual institution guidelines were most commonly used (47%). Key discrepancies between reported antiemetic use and guideline recommendations in the highly emetogenic chemotherapy (HEC) setting were underutilization of the recommended NK1RA + 5-HT3RA + steroid combination on day 1 (55%) and high use of 5-HT3RAs (50%) on days 2–5 when a steroid (63% use) should be used. Metoclopramide use was high in both HEC and moderately emetogenic settings, with ~ 30% and ~ 50% reporting use on day 1 and days 2–5, respectively. The most common reported barrier to use of guideline-recommended agents was physician preference (40%). The most common challenges in managing CINV were “controlling nausea/vomiting in the delayed phase” (64%) and “reducing the impact of CINV on patients’ quality-of-life” (61%). This survey highlights opportunities to improve utilization of guideline-recommended antiemetics, thereby optimizing prevention of CINV and QoL for patients receiving emetogenic chemotherapy.
Margaret Rosenzweig - One of the best experts on this subject based on the ideXlab platform.
-
Mentorship for Nurse Scientists: Strategies for Growth From the Oncology Nursing Society Research Mentorship Task Force.
Oncology Nursing Forum, 2019Co-Authors: Margaret Rosenzweig, Kathi Mooney, Donald E. Bailey, Nancy Jo Bush, Lorinda A. Coombs, Rebecca H. Lehto, Victoria Loerzel, Virginia Sun, Mary E. CooleyAbstract:PROBLEM STATEMENT To describe research mentorship strategies needed to strengthen Oncology nursing science and ensure that a cadre of Nurse scientists are available to carry out the research mission of the Oncology Nursing Society (ONS). DESIGN Multimethod consensus-building approach by content experts of the ONS Research Mentorship Task Force and approval by the ONS Board of Directors was employed. DATA SOURCES Expert opinion, surveys, notes from an all-day research mentorship retreat, and literature review were used. ANALYSIS Content analysis was used to synthesize notes from the research mentorship retreat. FINDINGS Various strategies were identified to strengthen the pipeline of Oncology Nurse scientists and promote development across the career trajectory. IMPLICATIONS FOR PRACTICE Mentorship is essential to advance the growth and impact of Oncology nursing science and requires support throughout the career trajectory.
-
Oncology Nurse practitioner web education resource onc power an evaluation of a web enhanced education resource for Nurse practitioners who are new to cancer care
Journal of the advanced practitioner in oncology, 2018Co-Authors: Rosemary L Hoffmann, Sara Klein, Mary Connolly, Margaret RosenzweigAbstract:The Nurse practitioner (NP) new to an advanced role in a specialty practice may find the orientation period challenging while expanding his or her professional knowledge base. The Oncology Nurse Practitioner Web Education Resource (ONc-PoWER), a web-enhanced continuing education program, provides training for both the Oncology NP (ONP) new to cancer care (i.e., within the first year) and his or her on-site mentor. The Oncology Nurse Practitioner Web Education Resource promotes essential didactic and skills development via five modules. A total of 103 dyads (i.e., a new ONP and his or her mentor) were recruited from 27 states to participate in ONc-PoWER, and 79 dyads completed surveys to evaluate the program. Data were collected between April 2012 and October 2016. We observed statistical significance (p = .000) between pre- and post-program self-assessment of cancer care knowledge and confidence in delivering cancer care among ONPs. Moreover, mentors rated the program favorably. Mentor agreement concerning whether or not the ONPs were able to successfully perform 30 core clinical skills ranged from a low of 93% to a high of 100%. Furthermore, mean scores of the course satisfaction survey demonstrate that each ONc-PoWER objective either met or exceeded learner expectations.
-
bridging the gap a descriptive study of knowledge and skill needs in the first year of Oncology Nurse practitioner practice
Oncology Nursing Forum, 2012Co-Authors: Margaret Rosenzweig, Joan Giblin, Marsha Mickle, Allison Morse, Patricia Sheehy, Valerie SommerAbstract:PURPOSE/OBJECTIVES To identify the knowledge and skill needs of Oncology Nurse practitioners (ONPs) as they enter cancer care practice, and to identify necessary educational resources. DESIGN Cross-sectional, descriptive. SETTING A national e-mail survey. SAMPLE 610 self-described ONPs from the Oncology Nursing Society's database. METHODS The project team developed a 28-item electronic survey. The survey was randomly distributed via e-mail. MAIN RESEARCH VARIABLES ONPs' feelings of preparedness in the first year of ONP practice. FINDINGS In the first year of practice, 90% of ONPs rated themselves as prepared or very prepared in obtaining patient history, performing physical examination, and documenting findings. ONPs rated themselves as not at all or somewhat prepared in clinical issues of chemotherapy/biotherapy competency (n = 81, 78%), recognizing and managing oncologic emergencies, (n = 77, 70%), and recognizing and managing drug toxicities (n = 63, 61%). The primary source of Oncology education for ONPs new to practice was almost exclusively the collaborating or supervising physician (n = 84, 81%). CONCLUSIONS Specific knowledge and skills, such as information about chemotherapy, oncologic emergencies, and side effects of therapy, are needed before an ONP enters a cancer care practice. IMPLICATIONS FOR NURSING Cancer-specific education should be made available to new ONPs as they begin independent practice.
-
filling the gap development of the Oncology Nurse practitioner workforce
Journal of Oncology Practice, 2010Co-Authors: Brenda Nevidjon, Margaret Rosenzweig, Cynthia Miller Murphy, Michele Mccorkle, Paula T Rieger, Kristen BaileysAbstract:A new strategy for Oncology care delivery that includes increasing the numbers and expanding the roles of nonphysician practitioners is critically important to meet the current and potential cancer care needs of the US population.
Sussanne Börjeson - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European Oncology Nurse survey
Supportive Care in Cancer, 2019Co-Authors: Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick JahnAbstract:IntroductionPreventing CINV is possible when guideline-recommended antiemetics are used. Because Oncology Nurses play a critical role in risk assessment and management of CINV, a survey of European Nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence.MethodsFrom March 2016 to Feb 2017, 212 Oncology Nurses in 16 European countries completed a 20-question online survey.ResultsRespondents had 15-year (median) Oncology nursing experience, and most (75%) were able to suggest or prescribe antiemetics. Most (80%) worked in the public not-for-profit hospital setting. Guideline awareness was generally low with Nurses most familiar with ASCO (46%) and MASCC/ESMO (40%) guidelines; individual institution guidelines were most commonly used (47%). Key discrepancies between reported antiemetic use and guideline recommendations in the highly emetogenic chemotherapy (HEC) setting were underutilization of the recommended NK_1RA + 5-HT_3RA + steroid combination on day 1 (55%) and high use of 5-HT_3RAs (50%) on days 2–5 when a steroid (63% use) should be used. Metoclopramide use was high in both HEC and moderately emetogenic settings, with ~ 30% and ~ 50% reporting use on day 1 and days 2–5, respectively. The most common reported barrier to use of guideline-recommended agents was physician preference (40%). The most common challenges in managing CINV were “controlling nausea/vomiting in the delayed phase” (64%) and “reducing the impact of CINV on patients’ quality-of-life” (61%).ConclusionsThis survey highlights opportunities to improve utilization of guideline-recommended antiemetics, thereby optimizing prevention of CINV and QoL for patients receiving emetogenic chemotherapy.
-
evaluation of antiemetic practices for prevention of chemotherapy induced nausea and vomiting cinv results of a european Oncology Nurse survey
Supportive Care in Cancer, 2019Co-Authors: Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick JahnAbstract:Preventing CINV is possible when guideline-recommended antiemetics are used. Because Oncology Nurses play a critical role in risk assessment and management of CINV, a survey of European Nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence. From March 2016 to Feb 2017, 212 Oncology Nurses in 16 European countries completed a 20-question online survey. Respondents had 15-year (median) Oncology nursing experience, and most (75%) were able to suggest or prescribe antiemetics. Most (80%) worked in the public not-for-profit hospital setting. Guideline awareness was generally low with Nurses most familiar with ASCO (46%) and MASCC/ESMO (40%) guidelines; individual institution guidelines were most commonly used (47%). Key discrepancies between reported antiemetic use and guideline recommendations in the highly emetogenic chemotherapy (HEC) setting were underutilization of the recommended NK1RA + 5-HT3RA + steroid combination on day 1 (55%) and high use of 5-HT3RAs (50%) on days 2–5 when a steroid (63% use) should be used. Metoclopramide use was high in both HEC and moderately emetogenic settings, with ~ 30% and ~ 50% reporting use on day 1 and days 2–5, respectively. The most common reported barrier to use of guideline-recommended agents was physician preference (40%). The most common challenges in managing CINV were “controlling nausea/vomiting in the delayed phase” (64%) and “reducing the impact of CINV on patients’ quality-of-life” (61%). This survey highlights opportunities to improve utilization of guideline-recommended antiemetics, thereby optimizing prevention of CINV and QoL for patients receiving emetogenic chemotherapy.
